Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages

Journal of Interferon and Cytokine Research

Volumn 16, Issue 10, 1996, Pages 805-812

  Fleischmann, Christina M ^a   Stanton, G John ^a   Fleischmann Jr , W Robert ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; H2 ANTIGEN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA INTERFERON AD; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 1; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SENSITIVITY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LIFESPAN; LYMPHOCYTE DEPLETION; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SUPPRESSOR CELL;

ANIMALIA;

EID: 0029977907     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.805     Document Type: Article

References (32)

1. FLEISCHMANN, C.M., and FLEISCHMANN, W.R., Jr. (1988). Differential antiproliferative activities of IFNs α, β, and γ: kinetics of establishment of their antiproliferative effects and the rapid development of resistance to IFNs α and β. J. Biol. Regul. Homeost. Agents 2, 173-185.
2. FLEISCHMANN, C.M., STANTON, G.J., and FLEISCHMANN, W.R., Jr. (1994). Enhanced in vivo sensitivity to interferon with in vitro-resistant B16 tumor cells in mice. Cancer Immunol. Immunother. 39, 148-154.
3. FLEISCHMANN, W.R., Jr., and FLEISCHMANN, C.M. (1992). Mechanisms of interferons' antitumor actions. In: Interferon: Principles and Medical Applications. S. Baron, D. Coppenhaver, F. Dianzani, et al. (eds.) Galveston: The University of Texas Medical Branch, pp. 299-310.
4. FIDLER, I.J. (1973). Selection of successive tumor lines for metastasis. Nature New Biol. 242, 148-149.
5. CAMPBELL, J.B., GRUNBERGER, T., KOCHMAN, M.A., and WHITE, S.L. (1975). A microplaque reduction assay for human and mouse interferon. Can. J. Microbiol. 21, 1247-1253.
6. LEDBETTER, J., and HERZENBERG, L. (1979). Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol. Rev. 47, 63-87.
7. LOKEN, M., and STALL, A. (1982). Flow cytometry as an analytical and preparative tool in immunology. J. Immunol. Methods 50, R85-112.
8. ALLISON, A., HARINGTON, J., and BIRBECK, M. (1966). An examination of the cytotoxic effects of silica on macrophages. J. Exp. Med. 124, 141-154.
9. BELARDELLI, F., GRESSER, I., MAURY, C., and MAUNOURY, M.-T. (1982). Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms. Int. J. Cancer 30, 821-825.
10. ZOLLER, M. (1988). IFN-treatment of B16-F1 versus B16-F10: relative impact on nonadaptive and T-cell-mediated immune defense in metastatic spread. Clin. Expl. Metastasis 6, 411-429.
11. BANNERJI, R., ARROYO, C., CORDON-DARDO, C., and GILBOA, E. (1994). The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol. 152, 2324-2232.
12. HABU, S., FUKUI, H., SHIMAMURA, K., et al. (1981). In vivo effects of anti-asialo GM1. J. Immunol. 127, 34-38.
13. MARKOVIC, S., and MURASKO, D. (1991). Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma. Cancer Res. 51, 1124-1128.
14. GRESSER, I., MAURY, C., CARNAUD, C., DE MAEYER, E., MAUNOURY, M.-T., and BELARDELLI, F. (1990). Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases. Int. J. Cancer 46, 468-474.
15. STUEHR, D.J., and NATHAN, C.F. (1989). Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169, 1543-1555.
16. SALKOWSKI, C., and VOGEL, S. (1992). IFN-γ mediates increased glucocorticoid receptor expression in murine macrophages. J. Immunol. 148, 2770-2777.
17. CARSWELL, E., OLD, L., KASSEL, R., GREEN, S., FIORE, N., and WILLIAMSON, B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3670.
18. GRESSER, I., BELARDELLI, F., TAVERNIER, J., et al. (1986). Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. V. Comparisons with the action of tumor necrosis factor. Int. J. Cancer 38, 771-778.
19. HARANAKA, K., SATOMI, N., and SAKURAI, A. (1984). Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int. J. Cancer 34, 263-267.
20. LACHMAN, L.B., DINARELLO, C.A., LIANSA, N.D., and FIDLER, I.J. (1986). Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells. J. Immunol. 136, 3098-3102.
21. ONOZAKI, K., MATUSHIMA, K., AGGARWAL, B.B., and OPPENHEIM, J.J. (1985). Human interleukin 1 is cytocidal for several tumor cell lines. J. Immunol. 135, 3962-3968.
22. CUI, S., REICHNER, J.S., MATEO, R.B., and ALBINA, J.E. (1994). Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res. 54, 2462-2467.
23. DILEEPAN, K.N., PAGE, J.C., LI, Y., and STECHSCHULTE, D.J. (1995). Direct activation of murine peritoneal macrophages for nitric oxide production and tumor cell killing by interferon-γ. J. Interferon Cytokine Res. 15, 387-394.
24. ZINKERNAGEL, R., and DOHERTY, P. (1979). MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. In: Advances in Immunology. H. Kunkel and F. Dixon (eds.) New York: Academic Press, pp. 51-177.
25. BLACKMORE, M., THOMPSON, S., and TURNER, G. (1990). A detailed study of the effects of in vitro interferon treatment on the growth of two variants of the B16 mouse melanoma in the lungs: evidence for non-specific effects. Clin. Exp. Metastasis 8, 449-460.
26. SAKURAI, M., MASAAKI, I., OZAKI, A., JETT, J.R., SASAKI, Y., HOSHI, A., and SAIJO, N. (1986). Inhibitory effect of murine recombinant interferon (β) on the pulmonary metastasis of B-16 melanoma. Jpn. J. Cancer Res. (Gann) 77, 774-781.
27. NISHIMURA, J., MITSUI, K., TANAKA, Y., YAMAMOTO, R., SUHARA, Y., and ISHITSUKA, H. (1986). Restoration by recombinant interferon alpha A/D of host defense systems against tumor in immunosuppressed mice. Clin. Exp. Metastasis 4, 35-44.
28. BRUNDA, M.J., WRIGHT, R.B., LUISTRO, L., HARBISON, M.L., ANDERSON, T.D., and McINTYRE, K.W. (1994). Enhanced antitumor efficacy in mice by combination treatment with interleukin-1α and interferon-α. J. Immunother. 15, 233-241.
29. BRUNDA, M.J., ROSENBAUM, D., and STERN, L. (1984). Inhibitionof experimentally induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases. Int. J. Cancer 34, 421-426.
30. PLASKIN, D., PORGADOR, A., VADAI, E., FELDMAN, M., SCHIRRMACHER, V., and EISENBACH, L. (1994). Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int. J. Cancer 59, 796-801.
31. b gene transfected tumour cells. Br. J. Cancer 68, 862-867.
32. BARTH, R.J., MULE, J.J., SPIESS, P.J., and ROSENBERG, S.A. (1991). Interferon-γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J. Exp. Med. 173, 647-658.